Barclays PLC Increases Holdings in BioLife Solutions, Inc. (NASDAQ:BLFS)

Barclays PLC grew its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 20.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 64,423 shares of the medical equipment provider’s stock after acquiring an additional 10,803 shares during the quarter. Barclays PLC owned 0.14% of BioLife Solutions worth $1,613,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. State Street Corp boosted its stake in BioLife Solutions by 7.3% in the 3rd quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after purchasing an additional 95,788 shares in the last quarter. Stifel Financial Corp raised its holdings in BioLife Solutions by 5.4% in the third quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock worth $325,000 after buying an additional 670 shares during the last quarter. Mark Sheptoff Financial Planning LLC bought a new position in shares of BioLife Solutions in the third quarter worth approximately $28,000. Rockefeller Capital Management L.P. grew its holdings in shares of BioLife Solutions by 81.3% during the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock valued at $14,661,000 after buying an additional 262,504 shares during the last quarter. Finally, FMR LLC increased its position in shares of BioLife Solutions by 470.6% during the third quarter. FMR LLC now owns 13,317 shares of the medical equipment provider’s stock valued at $333,000 after acquiring an additional 10,983 shares in the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

BioLife Solutions Stock Down 1.6 %

BLFS stock opened at $26.59 on Friday. BioLife Solutions, Inc. has a fifty-two week low of $14.50 and a fifty-two week high of $28.88. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -25.08 and a beta of 1.91. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The business’s 50-day moving average is $25.22 and its two-hundred day moving average is $23.88.

Analyst Ratings Changes

BLFS has been the topic of several analyst reports. KeyCorp upped their price objective on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Craig Hallum upped their price target on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. HC Wainwright reduced their price objective on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a report on Monday, November 18th. TD Cowen boosted their target price on BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Finally, Benchmark reaffirmed a “buy” rating and set a $30.00 price target on shares of BioLife Solutions in a report on Thursday, December 19th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, BioLife Solutions has an average rating of “Moderate Buy” and an average target price of $29.00.

Insider Buying and Selling

In related news, EVP Aby J. Mathew sold 25,000 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $21.17, for a total value of $529,250.00. Following the transaction, the executive vice president now directly owns 302,046 shares of the company’s stock, valued at approximately $6,394,313.82. This trade represents a 7.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders have sold 64,259 shares of company stock valued at $1,424,708. 2.20% of the stock is owned by insiders.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.